48,536
edits
Difference between revisions of "Invasive breast cancer"
Jump to navigation
Jump to search
m
→Standard IHC work-up: fixes
(→Standard work-up: add table) |
m (→Standard IHC work-up: fixes) |
||
| Line 22: | Line 22: | ||
**Usually negative; -ve in 70-80%.<ref>Lester. 2nd Ed. PP.241-2.</ref> | **Usually negative; -ve in 70-80%.<ref>Lester. 2nd Ed. PP.241-2.</ref> | ||
**Positivity association with a worse prognosis. | **Positivity association with a worse prognosis. | ||
===ER & PR scoring<ref>Lester. 2nd Ed. PP.241-2.</ref>=== | ===ER & PR scoring<ref>Lester. 2nd Ed. PP.241-2.</ref>=== | ||
| Line 30: | Line 29: | ||
***<10% = low positivity - treated. | ***<10% = low positivity - treated. | ||
Notes: | |||
*Normal breast epithelial cells have a patchy staining for ER and PR. | |||
*Evaluated on the invasive component. | |||
===HER2 scoring<ref>Lester. 2nd Ed. PP.241-2.</ref>=== | ===HER2 scoring<ref>Lester. 2nd Ed. PP.241-2.</ref>=== | ||
{| class="wikitable" | {| class="wikitable" | ||
| Line 68: | Line 70: | ||
|} | |} | ||
Notes: | |||
*Normal breast epithelial cells do not stain with HER2. | |||
*Evaluated on the invasive component. | |||
===Clinical=== | ===Clinical=== | ||
*ER & PR status determine whether a patient will get tamoxifen or other estrogen modulators. | *ER & PR status determine whether a patient will get tamoxifen or other estrogen modulators. | ||